预防紫杉烷类药物诱导的皮肤不良事件的干预措施评价:一项系统综述
该系统综述检索了1980年1月1日至2018年8月13日的PubMed和Scopus数据库,纳入34项原始研究报告,共涉及5647名参与者,评估预防紫杉烷诱导脱发及甲和皮肤改变的干预措施的有效性与安全性。在21项研究中20项(95%)支持使用冷帽或头皮冷却系统减少脱发,但疗效因化疗方案而异;8项研究中7项(88%)认为冷冻手套和冷冻袜预防甲及手足皮肤毒性是安全的。作者结论认为头皮低温疗法作为单药治疗预防紫杉烷诱导脱发已显示疗效,冷冻手套和袜子与减少甲和皮肤改变相关。
要点
- 21项研究中20项(95%)支持冷帽或头皮冷却系统减少紫杉烷相关脱发,但疗效因化疗方案而异。
- 8项研究中7项(88%)认为冷冻手套和冷冻袜预防甲及手足皮肤毒性是安全的,但不适感常见,1例患者出现冻伤。
- 6项研究中4项(67%)支持使用冷冻手套预防甲毒性,5项研究中3项(60%)支持预防手部皮肤改变。
核心结论
- 头皮低温疗法(冷帽或头皮冷却系统)作为单药治疗在预防紫杉烷诱导脱发方面已显示疗效。
- 使用冷冻手套和冷冻袜与减少甲和皮肤改变相关。
- 未来研究应确立常规使用方案、标准化结局指标以及这些干预措施的长期疗效和安全性。
研究设计与样本
- 系统综述检索PubMed和Scopus数据库,纳入1980年1月1日至2018年8月13日发表的英文研究。
- 纳入34项原始报告:6项随机临床试验、4项非随机临床试验、18项队列研究、3项病例对照研究、1项横断面研究和2项病例报告,共涉及5647名唯一参与者。
- 22项研究涉及紫杉烷相关脱发的预防干预,12项研究关注紫杉烷诱导的皮肤和甲改变。
- 研究结果根据改良自牛津循证医学中心的5分制量表进行分级。
主要发现
- 21项研究中20项(95%)支持使用冷帽或头皮冷却系统减少脱发,但疗效因化疗方案而异。
- 所有相关研究普遍认为头皮冷却安全,尽管有1例头皮皮肤转移的报告。
- 8项研究中7项(88%)认为冷冻手套和冷冻袜预防甲及手足皮肤毒性是安全的,但不适感常见,1例患者出现冻伤。
- 6项研究中4项(67%)支持使用冷冻手套预防甲毒性,5项研究中3项(60%)支持预防手部皮肤改变。
关键数值与推荐
- 脱发预防:21项研究中20项(95%)支持冷帽或头皮冷却系统,疗效因化疗方案而异。
- 甲毒性预防:6项研究中4项(67%)支持冷冻手套。
- 手部皮肤改变预防:5项研究中3项(60%)支持冷冻手套。
- 安全性:8项研究中7项(88%)认为冷冻手套和冷冻袜安全,1例患者出现冻伤,1例报告头皮皮肤转移。
临床怎么用
- 原文未据此给出推荐。
局限性
- 未来研究应确立常规使用方案、标准化结局指标以及这些干预措施的长期疗效和安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Chemotherapy-induced alopecia as well as nail and cutaneous changes occur in up to 89% of patients receiving taxane-based chemotherapy and are associated with cosmetic concerns, psychosocial distress, and overall morbidity. OBJECTIVE: To review the efficacy and safety of interventions to prevent taxane-induced dermatologic adverse events. EVIDENCE REVIEW: PubMed and Scopus databases were systematically reviewed for studies published in the English language from January 1, 1980, to August 13, 2018. Specific search terms included but were not limited to taxane, docetaxel, paclitaxel, prevent, nail, skin, hair, alopecia, and onycholysis. Primary clinical studies that detailed preventive interventions for taxane-induced dermatologic adverse events and that classified results according to a taxane-specific chemotherapy regimen were reviewed and graded according to a 5-point scale, modified from the Oxford Centre for Evidence-based Medicine. FINDINGS: The 34 original reports that met the inclusion criteria consisted of 6 randomized clinical trials, 4 nonrandomized clinical trials, 18 cohort studies, 3 case-control studies, 1 cross-sectional study, and 2 case reports and involved a total of 5647 unique participants. A total of 22 studies addressed preventive interventions for alopecia associated with taxane use, whereas 12 studies focused on taxane-induced skin and nail changes. Specifically, 20 (95%) of 21 studies supported the use of either a cold cap or a scalp cooling system to reduce alopecia but reported substantial differences in efficacy depending on the chemotherapy regimen. Scalp cooling was generally considered safe by all pertinent studies despite a single report of scalp skin metastasis. Similarly, use of frozen gloves and frozen socks in the prevention of nail and cutaneous hand and foot toxic effects was considered safe in 7 (88%) of 8 studies, although discomfort was common and frostbite was noted in 1 patient. Overall, use of frozen gloves was endorsed by 4 (67%) of 6 studies to prevent nail toxic effects and by 3 (60%) of 5 studies to prevent cutaneous hand changes. CONCLUSIONS AND RELEVANCE: Scalp hypothermia with cold caps or scalp cooling systems has demonstrated efficacy as a monotherapy in preventing taxane-induced alopecia, and use of frozen gloves and socks has been associated with reduced nail and skin changes. Future studies should establish the routine usage protocols, standard outcome measures, and long-term efficacy and safety for these interventions.
引用
- Marks DH, Qureshi A, Friedman A, et al. Evaluation of Prevention Interventions for Taxane-Induced Dermatologic Adverse Events: A Systematic Review. JAMA Dermatol. 2018. PMID: 30383138. doi:10.1001/jamadermatol.2018.3465
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。